Biogen 주식 가격. 0R1B - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

277.67

매수가

0.00

매도가

0.00

거래량

3,758

0.00 일간 변동폭 0.00

277.67 52주 범위 277.67

market_cap

40.234B

전일 종가

277.67

개장가

최근 거래 시간

147.06828

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

4,754

발행 주식

144,898,000

배당수익률

주가수익률

18.28

주당순이익(EPS)

8.01

매출

9.84B

순이익

1.16B

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.biogen.com

본부

Wilmington, Delaware, USA

설립됨

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the 런던증권거래소 with ticker 0R1B. The last closing price for Biogen was US$277.67. Over the last year, Biogen shares have traded in a share price range of US$ 277.67 to US$ 277.67.

Biogen currently has 144,898,000 shares in issue. The market capitalisation of Biogen is US$40.23 billion. Biogen has a price to earnings ratio (PE ratio) of 18.28.

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance dosing may be easier for patients and care partners to...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease LEQEMBI is the only FDA-approved anti-amyloid...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...

기간	시가	고가	저가	평균 일일 거래량	VWAP
1	277.67	277.67	277.67	5153	277.67	DE
4	277.67	277.67	277.67	3987	277.67	DE
12	277.67	277.67	277.67	4754	277.67	DE
26	277.67	277.67	277.67	3660	277.67	DE
52	277.67	277.67	277.67	3590	277.67	DE
156	277.67	277.67	277.67	4672	277.67	DE
260	277.67	277.67	277.67	3990	277.67	DE

0R1B - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is US$ 277.67

How many Biogen shares are in issue?

Biogen has 144,898,000 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is USD 40.23B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of US$ 277.67 to US$ 277.67 during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 18.28

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2.16

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.84B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.16B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
GILDGuild Esports Plc	0.075p (66.67%)	157.61M
MSMNMosman Oil And Gas Limited	0.0375p (50.00%)	2.29B
MODER8 Capital Investments Plc	2.15p (43.33%)	7.61M
LENDSancus Lending Group Limited	0.60p (33.33%)	2.2M
KMKKromek Group Plc	6.65p (25.47%)	39.88M
FUMFutura Medical Plc	16.50p (-46.77%)	8.66M
RCDORicardo Plc	267.00p (-24.15%)	4.31M
PEGPetards Group Plc	6.50p (-18.75%)	706.63k
SCGLSealand Capital Galaxy Limited	6.50p (-14.47%)	5.09M
SIVSivota Plc	3.00p (-14.29%)	7.5k
MSMNMosman Oil And Gas Limited	0.0375p (50.00%)	2.29B
DKEDukemount Capital Plc	0.0545p (21.11%)	1.39B
EMEEmpyrean Energy Plc	0.115p (4.55%)	885.99M
TRPTower Resources Plc	0.0295p (3.51%)	470.89M
NTVONativo Resources Plc	0.0019p (0.00%)	309.74M